Astellas Pharma and Dyno Therapeutics have announced an option and license agreement to develop next-generation adeno-associated virus (AAV) vectors for gene therapy directed to skeletal and cardiac muscle using Dyno’s CapsidMap™ platform.
Dyno’s CapsidMap platform represents a new approach applying in vivo experimental data and machine learning to create novel AAV capsids designed to optimise tissue targeting and immune-evading properties, in addition to improving packaging capacity and manufacturability. This research collaboration combines Dyno’s AI-powered AAV vector engineering capabilities with Astellas Gene Therapies global leadership in AAV-based pipeline assets.
